Aromatase inhibitors in ovarian stimulation

摘要: The selective estrogen receptor modulator, clomiphene citrate (CC), has been the principal drug used for induction of ovulation in women with polycystic ovarian syndrome (PCOS). CC is associated adverse side effects and low pregnancy rates attributed to long-lasting depletion. Anastrozole letrozole are potent, non-steroidal, reversible aromatase inhibitors, developed postmenopausal breast cancer therapy. We hypothesized that inhibitors could mimic action reducing negative feedback on follicle stimulating hormone (FSH) secretion, without depleting receptors. In a series preliminary studies, we reported success inhibition inducing anovulatory PCOS. Moreover, showed concomitant use resulted significant reduction FSH dose needed controlled hyperstimulation. suggest act through an increase endogenous gonadotropin secretion as well increased intraovarian androgen levels may Recently, demonstrated safety outcome studies examining spontaneous loss, multiple congenital anomalies compared control group infertility patients treated CC.